City
Epaper

Effect of common COVID-19 antibiotic found similar to that of placebo

By ANI | Updated: July 17, 2021 08:40 IST

The findings of a new study from UC San Francisco suggests that among non-hospitalized patients the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19. Despite widespread prescription of the antibiotic for the disease, it might increase the chance of hospitalization.

Open in App

The findings of a new study from UC San Francisco suggests that among non-hospitalized patients the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19. Despite widespread prescription of the antibiotic for the disease, it might increase the chance of hospitalization.

The study, which was conducted in collaboration with Stanford University, appeared in the Journal of the American Medical Association.

"These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection," said lead author Catherine E. Oldenburg, ScD, MPH, an assistant professor with the UCSF Proctor Foundation. SARS-CoV-2 is the virus that causes COVID-19.

Azithromycin, a broad-spectrum antibiotic, is widely prescribed as a treatment for COVID-19 in the United States and the rest of the world. "The hypothesis is that it has anti-inflammatory properties that may help prevent progression if treated early in the disease," said Oldenburg. "We did not find this to be the case."

The study included 263 participants who all tested positive for SARS-CoV-2 within seven days before entering the study. None were hospitalized at the time of enrollment. In a random selection process, 171 participants received a single, 1.2-gram oral dose of azithromycin and 92 received an identical placebo.

At day 14 of the study, 50 percent of the participants remained symptom-free in both groups. By day 21, five of the participants who received azithromycin had been hospitalized with severe symptoms of COVID-19 and none of the placebo group had been hospitalized.

The researchers concluded that treatment with a single dose of azithromycin compared to placebo did not result in greater likelihood of being symptom-free.

"Most of the trials done so far with azithromycin have focused on hospitalized patients with pretty severe disease," said Oldenburg. "Our paper is one of the first placebo-controlled studies showing no role for azithromycin in outpatients."

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: JAMAStanford UniversitySan FranciscoUnited StatesThe statesSan francisco bayEuaJose d'saFar-westSuaUnited states state
Open in App

Related Stories

MaharashtraReligion Is One Consideration In Custody Cases, But Child Welfare Is Primary Factor: Bombay High Court

InternationalUS Visa Waiver Program: Can Indian Passport Holders Enter the US Without Visa? Citizens of 41 Countries Get Free Entry

OpinionsWill the Trump Card work Against China?

Business38% Fall In Gold Prices Over The Next 5 Years: Market Experts Predict Steep Decline Ahead?

OpinionsWhat do America’s Actions Mean?

Health Realted Stories

HealthNew AI breakthrough to revolutionise diagnosis, treatment of genetic diseases

HealthHidden virus found common in germs that cause pneumonia: Study

HealthSmriti Irani opens up about her ‘companion of thoughts’

HealthUS launches next-generation universal vaccine platform for pandemic-prone viruses

HealthSocial pension: Tripura govt sets up new help desk for cancer patients